KETOROLAC
Substance-Related Disorder
Wake Forest University Health SciencesSmall moleculePhase 3Active
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 89/ 100
Competitive context
22 Active assets in the Substance-Related Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
METHADONE Rutgers, The State University of New Jersey | Phase 4 | BBB |
HYDROMORPHON Endeavor Health | Phase 4 | BBB |
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Wake Forest University Health Sciences | Phase 4 | BBB |
Dexmedetomidine Kaohsiung Veterans General Hospital. | Phase 4 | BB |
FENTANYL University of Crete | Phase 4 | BB |
View all 26 →
Same molecule, other indications
KETOROLAC is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →